Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy
between this translated document and the Japanese original, the original shall prevail.

February 5, 2024

Consolidated Financial Results
for the Nine Months Ended December 31, 2023
(Under Japanese GAAP)
Company name:
Mochida Pharmaceutical Co., Ltd.
Listing:
Tokyo Stock Exchange
Securities code:
4534
URL:
https://www.mochida.co.jp/english/
Representative:(Name) Naoyuki Mochida (Title) Representative Director, President
Inquiries:(Name) Kenichi Miyamoto (Title) Head of Finance & Accounting Department
Telephone:+81-3-3358-7211
Scheduled date to file quarterly securities report:
February 13, 2024
Scheduled date to commence dividend payments:
Preparation of supplementary material on quarterly financial results: None
Holding of quarterly financial results briefing:
None(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the nine months ended December 31, 2023 (from April 1, 2023 toDecember 31, 2023)(1) Consolidated operating results (cumulative)
Net sales
Nine months ended(Percentages indicate year-on-year changes.)

Operating profit

Profit attributable toowners of parent

Ordinary profit

Millions of yen%

Millions of yen%

Millions of yen%

Millions of yen%

December 31, 2023

78,218

(3.9)

5,791

(44.1)

6,059(43.0)

4,444(45.0)

December 31, 2022

81,394(4.0)

10,356(20.6)

10,639(20.9)

8,081(20.6)

Note: Comprehensive income

Nine months ended

For the Nine months ended December 31, 2023:
For the Nine months ended December 31, 2022:

Basic earnings pershare

Diluted earnings pershare

Yen

Yen

December 31, 2023

123.48-December 31, 2022

216.47-¥6,536 million¥7,055 million[(7.4)%][2.9%](2) Consolidated financial position
Total assets
As ofNet assets

Equity-to-asset ratio

Millions of yen

Millions of yen

December 31, 2023

157,825

127,179

80.6

March 31, 2023

158,831

126,775

79.8

Reference: Equity
As of December 31, 2023:
As of March 31, 2023:¥127,179 million¥126,775 million%

2. Cash dividends
Annual dividends per shareFirstquarter-end

Secondquarter-end

Yen
Fiscal year ended

March 31, 2023
Fiscal year ending

March 31, 2024

Thirdquarter-end

Yen

Fiscal year-end

Yen-

40.00

--

40.00

-

Fiscal year ending

March 31, 2024 (Forecast)

TotalYen

Yen

40.00

80.00

40.00

80.00

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated financial result forecasts for the fiscal year ending March 31, 2024 (from April 1, 2023 toMarch 31, 2024)(Percentages indicate year-on-year changes.)
Net sales
Millions ofyen

Operating profit%

Millions ofyen

Profit attributable toowners of parent

Ordinary profit%

Millions ofyen

Full year
102,000(1.2)
5,500 (35.4)
5,700
Note: Revisions to the financial result forecast most recently announced: Yes

Basic earnings
per share%

Millions ofyen%

Yen(37.3)

4,400(33.8)

123.85* Notes(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in change inscope of consolidation): None
(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements:
Yes(3) Changes in accounting policies, changes in accounting estimates, and restatement(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None(ii) Changes in accounting policies due to other reasons: None(iii) Changes in accounting estimates: None(iv) Restatement: None
(4) Number of issued shares (common shares)(i)

Total number of issued shares at the end of the period (including treasury shares)
As of December 31, 2023

38,500,000 shares

As of March 31, 2023

38,500,000 shares(ii) Number of treasury shares at the end of the period
As of December 31, 2023

2,974,069 shares

As of March 31, 2023

1,967,279 shares(iii) Average number of shares outstanding during the period (cumulative)
Nine months ended December 31, 2023

35,993,295 shares

Nine months ended December 31, 2022

37,334,140 shares* Quarterly financial results reports are exempt from quarterly review conducted by certified public accountants
or an audit corporation.
* Explanation of the proper use of financial result forecasts and other special matters
The financial result forecasts presented in this document are based on information that is currently available to
the Company as of the announcement of this document, and the Company does not guarantee to achieve them.
In addition, actual financial results may differ significantly from these forecasts due to a wide range of factors.

Quarterly Consolidated Financial Statements(1) Quarterly Consolidated Balance Sheets(Millions of yen)
As of March 31, 2023
AssetsCurrent assets
Cash and deposits
Accounts receivable - trade
Securities
Merchandise and finished goods
Work in process
Raw materials and supplies
OtherTotal current assets
Non-current assets
Property, plant and equipment
Buildings and structures, net
Machinery, equipment and vehicles, net
Land
Other, net
Total property, plant and equipment
Intangible assets
Investments and other assets
Investment securities
Deferred tax assets
Other
Total investments and other assets
Total non-current assets
Total assets

1

As of December 31, 2023

47,01027,806
13,49914,644
1,453
8,307
4,656
117,379

29,90935,093
13,49917,795
2,016
9,971
5,235
113,522

7,069
1,854
4,990
1,135
15,049
797

6,904
1,791
5,993
1,142
15,832729

14,246
3,8837,476
25,60541,452
158,831

17,585
2,861
7,293
27,74144,302
157,825

(Millions of yen)
As of March 31, 2023
Liabilities
Current liabilities
Notes and accounts payable - trade
Electronically recorded obligations - operating
Income taxes payable
Provision for bonuses
Other provisions
Other
Total current liabilities
Non-current liabilities
Retirement benefit liability
Other
Total non-current liabilities
Total liabilities
Net assets
Shareholders’ equity
Share capital
Capital surplus
Retained earnings
Treasury shares
Total shareholders’ equity
Accumulated other comprehensive income
Valuation difference on available-for-sale securities
Remeasurements of defined benefit plans
Total accumulated other comprehensive income
Total net assets
Total liabilities and net assets

2

As of December 31, 2023

9,047
910
501
2,313
169
14,31627,258

11,139
1,369
626
1,183
167
11,36025,846

4,133
664
4,798
32,056

4,117
681
4,799
30,645

7,229
1,871
118,943(7,114)
120,930

7,229
1,871
120,501(10,360)
119,242

5,655
189
5,844
126,775
158,831

7,781
155
7,937
127,179
157,825

(2) Quarterly Consolidated Statements of Income and Comprehensive Income
Quarterly Consolidated Statements of Income
Nine Months Ended December 31(Millions of yen)

Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating profit
Non-operating income
Interest income
Dividend income
Other
Total non-operating income
Non-operating expenses
Interest expenses
Share of loss of entities accounted for using equity
methodCommission expenses
Other
Total non-operating expenses
Ordinary profit
Extraordinary income
Settlement income
Gain on sale of investment securities
Insurance claim income
Total extraordinary income
Extraordinary losses
Loss on sale and retirement of non-current assets
Expenses for disposal of fixed assets
Total extraordinary losses
Profit before income taxes
Income taxes
ProfitProfit attributable to owners of parent

For the nine months ended
December 31, 2022
81,39437,221
44,17333,816
10,356

For the nine months ended
December 31, 2023
78,21837,87540,34334,551
5,791

1
337
91
430

1363
106
471

—

1—

162

38
109
147
10,639

33
5203
6,059

8—
412

13
15—
28

44
—
44
10,6072,525
8,0818,081

31
1244
6,043
1,599
4,444
4,444

3

Quarterly Consolidated Statements of Comprehensive Income
Nine Months Ended December 31(Millions of yen)

ProfitOther comprehensive income
Valuation difference on available-for-sale securities
Remeasurements of defined benefit plans, net of tax
Total other comprehensive income
Comprehensive income
Comprehensive income attributable toComprehensive income attributable to owners of parent

For the nine months ended
December 31, 2022
8,081

For the nine months ended
December 31, 2023
4,444(993)(32)(1,026)
7,0552,126(34)
2,092
6,536

7,055

6,5364

Sales of Main Products（Nine months ended December 31, 2023)（Billions of yen）
Products

Fiscal year ended

Fiscal year ending

March 31, 2023

March 31, 2024

Apr-Dec

Apr-MarApr-Dec

Apr-Mar
forecast

Ninemonths
Y o Ychanges%Treatment of ulcerative colitis

Lialda®

10.4

13.5

11.0

15.0

+ 7%

Treatment for chronic constipation

Goofice®

5.3

6.9

5.9

7.6

+ 12%

Drug for hyperlipidemia andarteriosclerosis obliterans

Epadel

5.5

7.1

5.8

7.5+ 5%Treatment for chronic constipationMovicol®

4.2

5.4

4.5

5.8+ 7%

AntidepressantLexapro®

10.5

11.0

4.1

5.3

△ 61%

Gout and hyperuricemia

Urece®

1.7

2.2

2.5

3.4+ 50%

Treatment for pulmonary arterial
hypertension
Calcium channel blocker with a longacting hypotensive effectAnalgesic for chronic pain and pain
after tooth extraction

Treprost®

1.2

1.6

1.7

2.3

+ 40%

Atelec®

2.1

2.6

1.8

2.3

△ 13%

Tramcet®

2.3

2.9

1.8

2.2

△ 24%

Heparin Sodium
MOCHIDA

1.0

1.2

1.0

1.2+ 4%Dinagest

1.6

1.8

0.91.1△ 43%

Beselna

0.8

1.1

0.8

1.1+ 2%Omvoh®

-----

Generic drugs

21.6

29.5

23.7

31.9

+ 10%

Skin Care Products

4.6

5.9

5.0

6.3

+ 9%

Anticoagulant agent
Therapeutic agent for endometriosis,
adenomyosis and dysmenorrhea
Therapeutic agent for condyloma
acuminatum and actinic keratosis
Treatment of ulcerative colitis

Lexapro® sales of the fiscal year ended march 31, 2023 are the sum of Mochida's own sales and sales toMitsubishi Tanabe Pharma Corporation.
Atelec® sales are the sum of Atelec® and Atedio® sales.
Omvoh® was launched in June 2023.
Due to discussions with partners, sales and annual forecasts for Omvoh® are not disclosed.

5Development Pipeline【Ethical drug】
Development code
<Generic name>
ACT-541468<daridorexant>* MD-711<treprostinil>

MD-0901<mesalazine>

FYU-981<dotinurad>

MND-21<icosapent>Stage

Indications

Filed

Insomnia

Filed

Pulmonary hypertension
associated withinterstitial lung diseaseor combined pulmonary
fibrosis and emphysema

Formulation
OralRemarks<Development country>
Co-development with Idorsia Pharmaceuticals Japan<Japan>

Licensed-in from United Therapeutics Corporation

Inhalant In-house development<Japan>Phase Ⅲ

Ulcerative colitis（pediatric indication）

Oral

Licensed-in from Takeda Pharmaceuticals U.S.A., Inc.
In-house development<Japan>Phase Ⅲ

Gout andhyperuricemia(pediatric indication)

Oral

Co-development with FUJI YAKUHIN Co., Ltd.
<Japan>Phase Ⅲ

Hypertriglyceridemia

Oral

Collaboration with Sumitomo Pharma (Suzhou) Co., Ltd.
<China>【Medical device】
Development code or
Common nameｄMD-001

ｄMD-002

ｄMD-003

Nerve Cuff

Stage

Intended use or indications

Remarks<Development country>

Articular cartilage lesion

In-house development<Japan>Therapeutic
Cavernous nerve injury
exploratory study

In-house development<Japan>Therapeuticconfirmatorystudy

Post-operative adhesion

In-house development<Japan>Filed（510(k)）

Peripheral nerve injury

In-house development
<USA>

Filed

Stages of Medical devices are classified into “Therapeutic exploratory study” and “Therapeutic confirmatory study”.

＊ Updates from November 2, 2023

6